I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 23% ± 8% | |
| glutamatergic neuron | 3 studies | 30% ± 10% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 23% ± 8% | |
| glutamatergic neuron | 3 studies | 30% ± 10% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 4 studies | 20% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 100% | 4041.08 | 653 / 653 | 100% | 6.57 | 605 / 605 |
| prostate | 100% | 3448.78 | 245 / 245 | 100% | 6.36 | 501 / 502 |
| esophagus | 100% | 1992.70 | 1442 / 1445 | 100% | 5.29 | 183 / 183 |
| breast | 100% | 2035.03 | 459 / 459 | 100% | 5.69 | 1114 / 1118 |
| bladder | 100% | 2459.86 | 21 / 21 | 99% | 3.86 | 501 / 504 |
| intestine | 100% | 2515.11 | 966 / 966 | 99% | 4.47 | 523 / 527 |
| pancreas | 100% | 1838.99 | 327 / 328 | 99% | 5.22 | 177 / 178 |
| adrenal gland | 100% | 1856.65 | 258 / 258 | 99% | 7.16 | 228 / 230 |
| brain | 99% | 2063.62 | 2614 / 2642 | 100% | 7.00 | 704 / 705 |
| uterus | 100% | 2983.19 | 170 / 170 | 99% | 3.89 | 453 / 459 |
| kidney | 100% | 2299.34 | 89 / 89 | 99% | 7.70 | 889 / 901 |
| stomach | 100% | 1747.85 | 359 / 359 | 99% | 4.29 | 282 / 286 |
| lung | 100% | 2625.60 | 578 / 578 | 98% | 4.50 | 1130 / 1155 |
| ovary | 100% | 3158.24 | 180 / 180 | 96% | 3.32 | 413 / 430 |
| skin | 100% | 1456.88 | 1806 / 1809 | 91% | 3.99 | 431 / 472 |
| liver | 99% | 1147.42 | 223 / 226 | 90% | 2.90 | 367 / 406 |
| adipose | 100% | 1912.36 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 7.30 | 29 / 29 |
| spleen | 100% | 3631.00 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.51 | 1 / 1 |
| blood vessel | 100% | 2412.58 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 1403.87 | 852 / 861 | 0% | 0 | 0 / 0 |
| muscle | 95% | 850.90 | 766 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 3.21 | 41 / 45 |
| peripheral blood | 78% | 1037.54 | 723 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 71% | 2.51 | 57 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
| GO_0051607 | Biological process | defense response to virus |
| GO_0051865 | Biological process | protein autoubiquitination |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0003713 | Molecular function | transcription coactivator activity |
| GO_0008270 | Molecular function | zinc ion binding |
| Gene name | TRIM52 |
| Protein name | Tripartite motif containing 52 Alternative protein TRIM52 E3 ubiquitin-protein ligase TRIM52 (EC 2.3.2.27) (RING finger protein 102) (Tripartite motif-containing protein 52) Tripartite motif containing 52 (Tripartite motif-containing 52, isoform CRA_a) |
| Synonyms | RNF102 hCG_1793559 |
| Description | FUNCTION: E3 ubiquitin-protein ligase . Positively regulates the NF-kappa-B signaling pathway . .; FUNCTION: (Microbial infection) Exhibits antiviral activity against Japanese encephalitis virus (JEV). Ubiquitinates the viral non-structural protein 2 (NS2A) and targets it for proteasome-mediated degradation. . |
| Accessions | A0A8I5KXP2 A0A8I5KRY2 ENST00000685507.1 ENST00000503005.2 ENST00000611618.1 [Q96A61-1] A0A8I5KQM7 ENST00000688015.1 A0A8I5KW90 L0R6S5 A0A8I5KXQ2 Q96A61 ENST00000686030.1 A0A8I5KYD8 ENST00000691252.1 ENST00000510796.2 |
